

F. No. CT/86/18-DCG(I)

F. No. CT/18/000088
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Global Clinical Trial Division)
FDA Bhawan, Kotla Road, New Delhi-110002
Te No: 01123236965, Fax: 01123236971
E-mail: dci@nic.in

To,

M/s. Covance India Pharmaceutical Services Pvt. Ltd.,
S4, 424, 425, Level 4, MBC Park, Sai Nagar, Kasarwadavli,
Ghodbunder Road, Thane (West), Maharashtra – 400615, India.

Subject: Clinical trial titled “A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintenance Therapy in Patients whose Disease has not Progressed Following Standard of Care Platinum-Based Chemotherapy with Durvalumab in First-Line Stage IV Non-Small Cell Lung Cancer (ORION).”– regarding.

Reference: Your Application No. GCT/Form44/FF/2018/11797 (GCT/86/18) dated 30/Nov/2018.

Sir,

This Directorate has no objection to your conducting the subject mentioned clinical trial as per the provisions of Drugs & Cosmetics Rules under supervision of the investigators mentioned below and as per the **Protocol No: D9102C00001, Protocol Version 2.0, dated 17/Sep/2018** submitted to this Directorate.

1. Dr. Pavithran Keechilat, Amrita Institute of Medical Sciences (AIMS), Ponekkara P.O., Cochin-682041, Kerala, India.
2. Dr. Rajnish Vasant Nagarkar, HCG Manavata Cancer Centre, Behind Shivang Auto, Mumbai Naka, Nashik-422001, Maharashtra, India.
3. Dr. Surender Kumar Beniwal, Department of Medical Oncology, ATRCTRI (RCC), S.P. Medical College & AG of Hospitals, Bikaner, 334003, Rajasthan, India.
4. Dr. Harsha P. Panchal, The Gujarat Cancer & Research Institute, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat, 380016, India.
5. Dr. Chirag Jyotiker Desai, Hemato Oncology Clinic Ahmedabad Pvt. Ltd., 1st Floor, Vedanta Institute of Medical Sciece, Near Samved Hospital, Stadium Commerce College Road, Navrangpura, Ahmedabad-380009, Gujarat, India.
6. Dr. K. C. Lakshmaiah, Srinivasam Cancer Care Multispeciality Hospital India Pvt. Ltd., No. 36, 1st A Main, 5th Cross Nethravathi Street, Maruthi Nagar, Nagarbhavi Main Road, Bangalore-560072, India.
7. Dr. Anish Maru, Shalby Hospital, Block F, Sector 3, Near Gandhi Path, Chitrakoot, Jaipur-302021, Rajasthan, India.
8. Dr. Minish Mahendra Jain, Grant Medical Foundation, Ruby Hall Clinic, 40, Sassoon Road, Pune-411001, Maharashtra, India.

F. No. CT/86/18-DCG(I)

9. Dr. Vikas Laxman, Department of Oncology, K.R. Hospital, Mysore Medical College & Research Institute, Irwin Road, Mysuru-570001, Karnataka, India.
10. Dr. Roshni Sivasevan, Regional Cancer Centre, P.O. Box Bo: 2417, Medical College Campus, Thiruvananthapuram-695011, Kerala, India.
11. Dr. Shailesh Arjun Bondarde, Shatabdi Hospital, Suyojit Centre, Opp. Mahamarga Bus Stand, Mumbai Naka, Nashik-422005, Maharashtra, India.

Note that the clinical trial permission is subject to the following conditions:

- a. Clinical trial shall be conducted in compliance with the approved protocols, requirements of Schedule Y, Good Clinical Practice Guidelines issued by this Directorate and other applicable regulations.
- b. Approval of the Ethics Committee shall be obtained before initiation of the study.
- c. Clinical trials shall be registered at Clinical trials Registry of India before enrolling the first patient for the study.
- d. Annual status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Licensing Authority, and in case of termination of any clinical trial the detailed reasons for the same shall be communicated to the said Licensing Authority.
- e. Any report of serious adverse event occurring during clinical trial study to the subject, after due analysis, shall be forwarded within fourteen days of its occurrence as per Appendix XI and in compliance with the procedures prescribed in Schedule Y.
- f. In case of an injury or death during the study to the subjects, the applicant shall provide complete medical management and compensation in the case of trial related injury or death in accordance with rule 122 DAB and the procedures prescribed under Schedule Y, and the details of compensation provided in such cases shall be intimated to the Licensing Authority within thirty days of the receipt of the order of the said authority.
- g. The premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites shall be open to inspection by the officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to verify compliance to the requirements of Schedule Y, Good Clinical Practices guidelines for conduct of clinical trial in India and other applicable regulations.
- h. The Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites and the Investigator shall allow officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to enter with or without prior notice, any premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites to inspect, search and seize any record, data, document, books, investigational drugs,

F. No. CT/86/18-DCG(I)

etc. related to clinical trial and provide adequate replies to any queries raised by the inspecting authority in relation to the conduct of clinical trial.

- i. Clinical trial shall be conducted only at those sites which are institutes/hospitals having adequate emergency facilities and duly registered Institutional Ethics committees.
- j. The details of payment/honorarium/financial support/fees paid by the Sponsor to the Investigator(s) for conducting the study shall be made available to this directorate before initiation of each of the trial sites.
- k. An audio-video recording of the informed consent process in case of vulnerable subjects in clinical trials of New Chemical Entity or New Molecular Entity including procedure of providing information to the subject and his understanding on such consent, shall be maintained by the investigator for record. Provided that in case of clinical trial of anti-HIV and anti-Leprosy drugs, only audio recording of the informed consent process of individual subject including the procedure of providing information to the subject and his understanding on such consent shall be maintained by the investigator for record.
- l. It may kindly be noted that merely granting permission to conduct clinical trials with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.
- m. Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect as per the requirements specified in Appendix V of Schedule Y of the Drugs and Cosmetics Rules, 1945 must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

Yours faithfully,

(Dr. S. Eswara Reddy)
Drugs Controller General (India)